Fenofibrate, a PPARα activator, has been reported to reduce ET-1-caused cardiac hypertrophy through downregulation of activating protein-1 (AP-1) binding and inhibition of p38 mitogen-activated protein kinases (MAPK) signaling [7, 8]. The gene discussed is MAPK14; the disease is cardiac hypertrophy.